Back to Search Start Over

Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration.

Authors :
Rademacher K
Doric Z
Haddad D
Mamaligas A
Liao SC
Creed RB
Kano K
Chatterton Z
Fu Y
Garcia JH
Vance V
Sei Y
Kreitzer A
Halliday GM
Nelson AB
Margolis EB
Nakamura K
Source :
BioRxiv : the preprint server for biology [bioRxiv] 2024 May 13. Date of Electronic Publication: 2024 May 13.
Publication Year :
2024

Abstract

Parkinson's disease (PD) is characterized by the death of substantia nigra (SNc) dopamine (DA) neurons, but the pathophysiological mechanisms that precede and drive their death remain unknown. The activity of DA neurons is likely altered in PD, but we understand little about if or how chronic changes in activity may contribute to degeneration. To address this question, we developed a chemogenetic (DREADD) mouse model to chronically increase DA neuron activity, and confirmed this increase using ex vivo electrophysiology. Chronic hyperactivation of DA neurons resulted in prolonged increases in locomotor activity during the light cycle and decreases during the dark cycle, consistent with chronic changes in DA release and circadian disturbances. We also observed early, preferential degeneration of SNc projections, recapitulating the PD hallmarks of selective vulnerability of SNc axons and the comparative resilience of ventral tegmental area axons. This was followed by eventual loss of midbrain DA neurons. Continuous DREADD activation resulted in a sustained increase in baseline calcium levels, supporting an important role for increased calcium in the neurodegeneration process. Finally, spatial transcriptomics from DREADD mice examining midbrain DA neurons and striatal targets, and cross-validation with human patient samples, provided insights into potential mechanisms of hyperactivity-induced toxicity and PD. Our results thus reveal the preferential vulnerability of SNc DA neurons to increased neural activity, and support a potential role for increased neural activity in driving degeneration in PD.<br />Competing Interests: Conflict of Interest Statement The authors declare no competing interests. Anatol Kreitzer’s current role is Chief Discovery Officer at Maplight Therapeutics.

Details

Language :
English
ISSN :
2692-8205
Database :
MEDLINE
Journal :
BioRxiv : the preprint server for biology
Publication Type :
Academic Journal
Accession number :
38645054
Full Text :
https://doi.org/10.1101/2024.04.05.588321